Literature DB >> 2805250

Central nervous system mechanisms involved in inhibition of renal sympathetic nerve activity induced by arginine vasopressin.

S Suzuki1, A Takeshita, T Imaizumi, Y Hirooka, M Yoshida, S Ando, M Nakamura.   

Abstract

Previous studies have suggested that intravenous infusion of arginine vasopressin (AVP) inhibits sympathetic nerve activity (SNA) in rabbits by its action at the brainstem. This study aimed to determine, first, whether this action of AVP depended on functioning baroreflex mechanisms. The second aim was to determine the role of the nucleus tractus solitarii (NTS) in mediating this action of AVP. Experiments were performed in rabbits anesthetized with alpha-chloralose. Intravenous infusions of AVP (1, 3, and 10 mU/kg/min) resulted in progressive inhibition of renal SNA in rabbits with intact arterial baroreceptors and vagal afferents as well as in rabbits with sinoaortic denervation and bilateral vagotomy. The magnitudes of renal SNA inhibition evoked with AVP were comparable in the two groups. Renal SNA inhibition evoked with AVP at doses of 1 and 3 mU/kg/min in rabbits after sinoaortic denervation and vagotomy was totally blocked by chemical lesions with kainic acid of the bilateral NTS or the area postrema. Lesions of the NTS or the area postrema markedly attenuated (by about 60%) but did not totally block the response evoked with AVP at a dose of 10 mU/kg/min. AVP microinjected directly into the NTS did not evoke changes in renal SNA or arterial pressure, whereas AVP microinjected into the area postrema suppressed renal SNA. These results suggest that intravenous AVP at lower doses inhibited renal SNA by causing excitation of the NTS neurons, and this action of AVP did not depend on functioning baroreflex mechanisms. The second suggestion is that the NTS was unlikely to be the site where AVP directly interacted but instead received a neural connection, presumably from the area postrema, where AVP might directly interact.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2805250     DOI: 10.1161/01.res.65.5.1390

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  5 in total

1.  Cardiovascular effects of felypressin.

Authors:  Rodrigo Cecanho; Laurival Antonio De Luca; José Ranali
Journal:  Anesth Prog       Date:  2006

2.  Sympathetic overactivity in patients with rheumatic mitral stenosis.

Authors:  Ozcan Ozdemir; Omer Alyan; Mustafa Soylu; Fatma Metin; Ahmet Duran Demir; Bilal Geyik; Dursun Aras; Cemal Ozbakir; Gökhan Cihan; Hatice Sasmaz; Sule Korkmaz
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-10       Impact factor: 1.468

3.  Vasodilatory effect of arginine vasopressin is mediated by nitric oxide in human forearm vessels.

Authors:  T Tagawa; T Imaizumi; T Endo; M Shiramoto; Y Hirooka; S Ando; A Takeshita
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

4.  Vasopressin and oxytocin in control of the cardiovascular system.

Authors:  Nina Japundžić-Žigon
Journal:  Curr Neuropharmacol       Date:  2013-03       Impact factor: 7.363

Review 5.  Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review.

Authors:  Nina Japundžić-Žigon; Maja Lozić; Olivera Šarenac; David Murphy
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.